<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spevak, Aimee</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kodali, Susheel</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">SAPIEN 3 TAVR System Produces Excellent Clinical Outcomes in PARTNER II Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-04-24 09:14:01</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">The PARTNER II trial investigated the use of the SAPIEN 3 transcatheter aortic valve replacement in patients who were high-risk/inoperable or intermediate-risk for surgical complications. Clinical outcomes were excellent, with low rates of adverse events and paravalvular leak.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>